Patents by Inventor DARKO SKEGRO

DARKO SKEGRO has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20200024367
    Abstract: The present invention relates to engineered hetero-dimeric immunoglobulins or fragments thereof and methods of making the same.
    Type: Application
    Filed: February 28, 2019
    Publication date: January 23, 2020
    Applicant: Glenmark Pharmaceuticals S.A.
    Inventors: Stanislas BLEIN, Darko SKEGRO, Paul WASSMANN
  • Publication number: 20190382475
    Abstract: The present invention provides heterodimeric antibodies and fragments thereof and methods for their preparation, wherein the pairing of heavy and light chains has been improved. Interface residues were mutated such that each light chain strongly favoured its cognate heavy chain when two different heavy chains and two different light chains were co-transfected and co-expressed in the same cell to assemble a functional, heterodimeric antibody or fragment thereof.
    Type: Application
    Filed: March 1, 2018
    Publication date: December 19, 2019
    Inventors: Regis CEBE, Sebastien IRIGARAY, Darko SKEGRO
  • Publication number: 20190135918
    Abstract: The present invention relates to hetero-dimeric immunoglobulins that target both a component of the human CD3 antigen and a component of the human CD38 antigen and methods of making the same. The present invention also relates to antibodies which bind to the human CD38 antigen and derivatives thereof for use as therapeutic or diagnostic reagents and methods of making the same.
    Type: Application
    Filed: October 12, 2018
    Publication date: May 9, 2019
    Applicant: GLENMARK PHARMACEUTICALS S.A.
    Inventors: Romain OLLIER, Samuel HOU, Rami LISSILAA, Darko SKEGRO, Jonathan BACK
  • Publication number: 20180355064
    Abstract: The present invention describes novel hetero-dimeric immunoglobulins or fragments thereof which bind to CD3 and a disease associated antigen. These hetero-dimeric immunoglobulins have been engineered to promote hetero-dimer formation during expression and can be purified to a high degree using a Protein A differential purification technique.
    Type: Application
    Filed: May 21, 2018
    Publication date: December 13, 2018
    Applicant: GLENMARK PHARMACEUTICALS S.A.
    Inventors: Stanislas BLEIN, Romain OLLIER, Darko SKEGRO, Samuel HOU
  • Publication number: 20180094077
    Abstract: The present invention relates to engineered hetero-dimeric immunoglobulins or fragments thereof and methods of making the same.
    Type: Application
    Filed: May 17, 2017
    Publication date: April 5, 2018
    Applicant: Glenmark Pharmaceuticals S.A.
    Inventors: Stanislas BLEIN, Darko Skegro, Paul Wassmann
  • Publication number: 20180086840
    Abstract: The present invention relates to antibodies or fragments thereof that bind to TL1A. More specifically, the present invention relates to an antibody or fragment thereof that binds to TL1A comprising a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 51, and/or a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 52, and/or a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 53; and/or comprising a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 54, and/or a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 55 and/or a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 56.
    Type: Application
    Filed: May 8, 2017
    Publication date: March 29, 2018
    Applicant: Glenmark Pharmaceuticals S. A.
    Inventors: Antoine ATTINGER, Jonathan Albert Back, Stanislas Blein, Rami Lissilaa, Darko Skegro
  • Publication number: 20170218087
    Abstract: The present invention relates to antibodies directed against TrkA receptor and their uses, including humanized anti-TrkA antibodies. More specifically, the present invention relates to humanized anti-TrkA antibodies with enhanced inhibitory properties comprising a heavy chain variable region, a light chain variable region, a human light chain constant region and a variant human IgG4 heavy chain constant region which exhibit altered exchange properties.
    Type: Application
    Filed: September 14, 2016
    Publication date: August 3, 2017
    Applicant: GLENMARK PHARMACEUTICALS S.A.
    Inventors: Stanislas BLEIN, Romain Ollier, Darko Skegro
  • Patent number: 9683052
    Abstract: The present invention relates to engineered hetero-dimeric immunoglobulins or fragments thereof and methods of making the same.
    Type: Grant
    Filed: March 23, 2012
    Date of Patent: June 20, 2017
    Assignee: Glenmark Pharmaceuticals S.A.
    Inventors: Stanislas Blein, Darko Skegro, Paul Wassmann
  • Patent number: 9683053
    Abstract: The present invention relates to engineered hetero-dimeric immunoglobulins or fragments thereof and methods of making the same.
    Type: Grant
    Filed: January 29, 2014
    Date of Patent: June 20, 2017
    Assignee: Glenmark Pharmaceuticals S.A.
    Inventors: Stanislas Blein, Darko Skegro, Paul Wassmann
  • Publication number: 20170145115
    Abstract: The present invention describes novel hetero-dimeric immunoglobulins or fragments thereof which bind to CD3 and a disease associated antigen. These hetero-dimeric immunoglobulins have been engineered to promote hetero-dimer formation during expression and can be purified to a high degree using a Protein A differential purification technique.
    Type: Application
    Filed: June 23, 2016
    Publication date: May 25, 2017
    Inventors: Stanislas BLEIN, Romain Ollier, Darko Skegro, Samuel Hou
  • Patent number: 9493563
    Abstract: The present invention describes novel hetero-dimeric immunoglobulins or fragments thereof which bind to CD3 and a disease associated antigen. These hetero-dimeric immunoglobulins have been engineered to promote hetero-dimer formation during expression and can be purified to a high degree using a Protein A differential purification technique.
    Type: Grant
    Filed: November 4, 2014
    Date of Patent: November 15, 2016
    Assignee: GLENMARK PHARMACEUTICALS S.A.
    Inventors: Stanislas Blein, Romain Ollier, Darko Skegro, Samuel Hou
  • Publication number: 20160319027
    Abstract: The present invention relates generally to antibodies directed against TrkA receptor and their uses, including humanized anti-TrkA antibodies and methods of treatment with anti-TrkA antibodies. In one aspect, the present invention relates to humanized anti-TrkA antibodies with enhanced inhibitory properties for use in methods of treating neuroma and/or bone associated pain.
    Type: Application
    Filed: April 6, 2016
    Publication date: November 3, 2016
    Inventors: Stanislas BLEIN, Romain OLLIER, Darko SKEGRO, Adrian WALMSLEY, Harald MOTTL
  • Patent number: 9290576
    Abstract: The present invention relates to antibodies or fragments thereof that bind to TL1A. More specifically, the present invention relates to an antibody or fragment thereof that binds to TL1A comprising a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 51, and/or a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 52, and/or a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 53; and/or comprising a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 54, and/or a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 55 and/or a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 56.
    Type: Grant
    Filed: January 2, 2014
    Date of Patent: March 22, 2016
    Assignee: GLENMARK PHARMACEUTICALS S.A.
    Inventors: Antoine Attinger, Jonathan Albert Back, Stanislas Blein, Rami Lissilaa, Darko Skegro
  • Publication number: 20150232559
    Abstract: The invention relates to antibodies directed to ?2?1 integrin and their uses, including humanized anti-alpha 2 (?2) integrin antibodies and methods of treatment with anti-?2 integrin antibodies. More specifically the present invention relates to humanized anti-?2 integrin antibodies comprising a heavy chain variable region, a light chain variable region, a human light chain constant region and a variant human IgG1 heavy chain constant region which exhibit altered effector function.
    Type: Application
    Filed: January 28, 2015
    Publication date: August 20, 2015
    Inventors: Stanislas Blein, Samuel Hou, Darko Skegro
  • Publication number: 20150183885
    Abstract: The present invention relates generally to antibodies directed against TrkA receptor and their uses, including humanized anti-TrkA antibodies and methods of treatment with anti-TrkA antibodies. In one aspect, the present invention relates to humanized anti-TrkA antibodies with enhanced inhibitory properties for use in methods of treating neuroma and/or bone associated pain.
    Type: Application
    Filed: December 5, 2014
    Publication date: July 2, 2015
    Inventors: Stanislas BLEIN, Romain Ollier, Darko Skegro, Adrian Walmsley, Harald Mottl
  • Publication number: 20150133640
    Abstract: The present invention describes novel hetero-dimeric immunoglobulins or fragments thereof which bind to CD3 and a disease associated antigen. These hetero-dimeric immunoglobulins have been engineered to promote hetero-dimer formation during expression and can be purified to a high degree using a Protein A differential purification technique.
    Type: Application
    Filed: November 4, 2014
    Publication date: May 14, 2015
    Inventors: Stanislas BLEIN, Romain Ollier, Darko Skegro, Samuel Hou
  • Patent number: 8975376
    Abstract: The invention relates to antibodies directed to ?2?1 integrin and their uses, including humanized anti-alpha 2 (?2) integrin antibodies and methods of treatment with anti-?2integrin antibodies. More specifically the present invention relates to humanized anti-?2 integrin antibodies comprising a heavy chain variable region, a light chain variable region, a human light chain constant region and a variant human IgG1 heavy chain constant region which exhibit altered effector function.
    Type: Grant
    Filed: February 22, 2011
    Date of Patent: March 10, 2015
    Assignee: Sanofi
    Inventors: Stanislas Blein, Samuel Hou, Darko Skegro
  • Publication number: 20140308271
    Abstract: The present invention relates to antibodies or fragments thereof that bind to TL1A. More specifically, the present invention relates to an antibody or fragment thereof that binds to TL1A comprising a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 51, and/or a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 52, and/or a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 53; and/or comprising a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 54, and/or a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 55 and/or a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 56.
    Type: Application
    Filed: January 2, 2014
    Publication date: October 16, 2014
    Applicant: GLENMARK PHARMACEUTICALS S.A.
    Inventors: ANTOINE ATTINGER, JONATHAN ALBERT BACK, STANISLAS BLEIN, RAMI LISSILAA, DARKO SKEGRO
  • Publication number: 20140286934
    Abstract: The present invention relates to humanized antibodies or fragments thereof that bind to human CD19. More specifically, the present invention relates to a humanized antibody or fragment thereof that binds to human CD19 comprising a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 27, and/or a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 28, and/or a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 29; and/or comprising a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 30, and/or a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 31 and/or a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 32.
    Type: Application
    Filed: January 30, 2014
    Publication date: September 25, 2014
    Applicant: GLENMARK PHARMACEUTICALS S.A.
    Inventors: Stanislas BLEIN, Darko Skegro, Christophe Debonneville, Martin Bertschinger
  • Publication number: 20140187753
    Abstract: The present invention relates to engineered hetero-dimeric immunoglobulins or fragments thereof and methods of making the same.
    Type: Application
    Filed: January 29, 2014
    Publication date: July 3, 2014
    Applicant: Glenmark Pharmaceuticals S.A.
    Inventors: Stanislas Blein, Darko Skegro, Paul Wassmann